By Tony Fong

NEW YORK (GenomeWeb News) – As next-generation sequencing makes its way into the clinic, platform vendors will need to change their operations to accommodate the shift, company executives said this week at the Burrill Personalized Medicine Meeting held in Burlingame, Calif.

Those changes include new emphases on different geographies, as well as disease areas, and new approaches to handling the data.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.